184 related articles for article (PubMed ID: 9484947)
1. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density.
Goldenberg JD; Portugal LG; Wenig BL; Ferrer K; Wu JC; Sabnani J
Head Neck; 1998 Mar; 20(2):152-8. PubMed ID: 9484947
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis as an indicator of metastatic potential in papillary thyroid carcinoma.
Stabenow E; Tavares MR; Ab'Saber AM; Parra-Cuentas ER; de Matos LL; Eher EM; Capelozzi VL; Ferraz AR
Clinics (Sao Paulo); 2005 Jun; 60(3):233-40. PubMed ID: 15962085
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
4. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance.
Akslen LA; Livolsi VA
Hum Pathol; 2000 Apr; 31(4):439-42. PubMed ID: 10821490
[TBL] [Abstract][Full Text] [Related]
5. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
6. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
7. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
8. Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma.
Sápi Z; Lukács G; Sztán M; Papp J; Oláh E
Diagn Mol Pathol; 1995 Dec; 4(4):256-60. PubMed ID: 8634781
[TBL] [Abstract][Full Text] [Related]
9. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
[TBL] [Abstract][Full Text] [Related]
10. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma.
Fontanini G; Vignati S; Pacini F; Pollina L; Basolo F
Mod Pathol; 1996 Jun; 9(6):636-41. PubMed ID: 8782200
[TBL] [Abstract][Full Text] [Related]
11. nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma.
Zafon C; Obiols G; Castellví J; Tallada N; Galofré P; Gemar E; Mesa J; Simó R
J Clin Endocrinol Metab; 2001 Aug; 86(8):3975-80. PubMed ID: 11502841
[TBL] [Abstract][Full Text] [Related]
12. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of metastatic lymph nodes from papillary thyroid carcinoma in adult and pediatric patients.
Shifrin AL; Fischer M; Paul T; Erler B; Gheysens K; Baodhankar P; Song-Yang JW; Taylor S; Timmaraju VA; Topilow A; Mireskandari A; Kumar G
Surgery; 2017 Jan; 161(1):176-187. PubMed ID: 27866718
[TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
15. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
Walts AE; Mirocha JM; Bose S
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in all stages of thyroid carcinomas.
Zou M; Shi Y; Farid NR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD34 in gastric cancer and its correlation with histology, stage, proliferation activity, p53 expression and apoptotic index.
Tenderenda M; Rutkowski P; Jesionek-Kupnicka D; Kubiak R
Pathol Oncol Res; 2001; 7(2):129-34. PubMed ID: 11458276
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors in differentiated thyroid gland carcinoma].
Fonseca E; Soares P; Rossi S; Sobrinho-Simões M
Pathologe; 1997 Jul; 18(4):275-85. PubMed ID: 9380603
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
[TBL] [Abstract][Full Text] [Related]
20. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
